Share
Intradiscal Autologous and Allogenic Products
Dr. Sudhir Diwan reviews research pertaining to intradiscal platelet-rich plasma (PRP) and stem cells. He also discusses warnings from the FDA regarding allogenic products. Dr. Diwan explains that the warnings are related to challenges in ensuring the safety and quality of allogenic products. He further mentions that allogenic cells are not patient specific and that this causes ethical as well as immunological issues.
Read More
To target these issues, Dr. Diwan emphasizes the use of stem cells that are extracted from the patient who will be treated through PRP-stem cell therapy. He mentions that this form of regenerative medicine is demonstrating evidence of a reduced need for more invasive procedures and helps slow the progression of certain diseases (e.g., degenerative disease) as demonstrated by tissue regeneration.
Read Less
Comment
expand_more
expand_less